Please note that LIDDS will disclose information in Press releases only in English going forward. Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska. LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months. Visitingadress: Virdings allé 32b, Uppsala LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.comPress releases
LIDDS Interim report January – September 2021 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer LIDDS patent covering the NanoZolid® production process granted in Russia and Australia LIDDS – subscription of warrantsEvents
Company Analysis
Photo Library
Video Library
Lidds
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.comFinancial Calendar
Subscribe for news
Press releases
LIDDS Interim report January – September 2021 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer LIDDS patent covering the NanoZolid® production process granted in Russia and Australia LIDDS – subscription of warrants
press
LIDDS genomför en riktad nyemission av aktier och tillförs cirka 45 Mkr
events
analysis
